Liat Adar

Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial

Alberto J. Espay, Fabrizio Stocchi, Rajesh Pahwa et al. · The Lancet Neurology · 2024 · 60 citations

Parkinson Disease, Clinical Neurology, Multicentre Trial +6

ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study

Nir Giladi, Tanya Gurevich, Ruth Djaldetti et al. · Parkinsonism & Related Disorders · 2021 · 48 citations · Full text

Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO‐B) Inhibitor Rasagiline

Tamar Goren, Liat Adar, Yoni M. Weiss · The Journal of Clinical Pharmacology · 2010 · 40 citations

Molecular Pharmacology, Medicinal Chemistry, Pharmacological Study +12

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1<scp>‐Year</scp> Data from the <scp>Open‐Label BeyoND</scp> Study

Werner Poewe, Fabrizio Stocchi, David Arkadir et al. · Movement Disorders · 2021 · 36 citations · Full text

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program

Peter A. LeWitt, Fabrizio Stocchi, David Arkadir et al. · Frontiers in Neurology · 2022 · 28 citations · Full text